adenine has been researched along with B-Cell Prolymphocytic Leukemia in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 3 (60.00) | 2.80 |
| Authors | Studies |
|---|---|
| Moore, J | 1 |
| Baran, AM | 1 |
| Meacham, PJ | 1 |
| Evans, AG | 1 |
| Barr, PM | 1 |
| Zent, CS | 1 |
| Oka, S | 1 |
| Ono, K | 1 |
| Nohgawa, M | 1 |
| George, P | 1 |
| Brown, A | 1 |
| Weinkove, R | 1 |
| Damlaj, M | 1 |
| Al Balwi, M | 1 |
| Al Mugairi, AM | 1 |
| Patil, N | 1 |
| Went, RG | 1 |
5 other studies available for adenine and B-Cell Prolymphocytic Leukemia
| Article | Year |
|---|---|
Initial treatment of B-cell prolymphocytic leukemia with ibrutinib.
Topics: Adenine; Aged; Female; Humans; Leukemia, Prolymphocytic, B-Cell; Male; Piperidines; Pyrazoles; Pyrim | 2020 |
Effective upfront treatment with low-dose ibrutinib for a patient with B cell prolymphocytic leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Antineoplastic Agents; Humans; Leukemia, Prolymp | 2020 |
B-cell prolymphocytic leukaemia with a t(4;14) FGFR3/IGH translocation: response to ibrutinib.
Topics: Adenine; Aged; Antineoplastic Agents; Humans; Leukemia, Prolymphocytic, B-Cell; Male; Piperidines; R | 2020 |
Ibrutinib therapy is effective in B-cell prolymphocytic leukemia exhibiting MYC aberrations.
Topics: Adenine; Aged; Gene Rearrangement; Humans; Leukemia, Prolymphocytic, B-Cell; Male; Piperidines; Prog | 2018 |
Venetoclax is an option in B-cell prolymphocytic leukaemia following progression on B-cell receptor pathway inhibitors.
Topics: Adenine; Aged; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Drug Substitution; Hu | 2019 |